Canine Leptospirosis: Clinical Signs, Diagnosis, and Zoonotic Risk Management

Introduction

Canine leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. The disease represents a significant diagnostic challenge due to its variable clinical presentation, overlapping signs with other systemic febrile illnesses, and the requirement for specialized laboratory confirmation. From a One Health perspective, dogs serve as both sentinel hosts and potential reservoirs for human infection, particularly in urban environments where contact with rodent urine and contaminated standing water is common [1, 2]. This article provides an exhaustive review of the clinical signs, serovar prevalence, diagnostic modalities (including the microscopic agglutination test (MAT) and polymerase chain reaction (PCR)), and zoonotic risk management strategies for veterinary practitioners.

Etiology and Serovar Classification

The genus Leptospira encompasses over 250 serovars grouped into 24 serogroups based on lipopolysaccharide (LPS) antigenic structure. Pathogenic species include L. interrogans, L. kirschneri, L. borgpetersenii, and L. noguchii, among others [3]. In dogs, the most frequently isolated serovars vary by geographic region but commonly include:

• Icterohaemorrhagiae (associated with rats)
• Canicola (historically associated with dogs as maintenance hosts)
• Grippotyphosa (associated with wildlife, particularly raccoons and opossums)
• Pomona (associated with livestock and wildlife)
• Australia and Autumnalis (increasingly reported in North America and Europe) [4, 5, 6]

Serovar distribution is dynamic and influenced by environmental changes, wildlife population shifts, and vaccination practices. Vaccination against serovars Canicola and Icterohaemorrhagiae has reduced the incidence of those serovars in vaccinated populations, yet nonvaccinal serovars (e.g., Grippotyphosa, Pomona, Autumnalis) have emerged as predominant causes of clinical disease in many regions [7, 8].

Pathogenesis and Host-Pathogen Interactions

Leptospira spp. penetrate the canine host through mucous membranes or abraded skin, then disseminate hematogenously. Spirochetes bind to host extracellular matrix components via adhesins such as LigA, LigB, and LipL32, facilitating endothelial attachment and tissue invasion [9]. The bacteria evade early innate immune responses through complement resistance mechanisms mediated by factor H binding proteins [10]. Major target organs include the kidneys (proximal renal tubules), liver (hepatocytes and Kupffer cells), and pulmonary endothelium.

Acute infection results in vasculitis, endothelial damage, and multiple organ dysfunction. Renal pathology manifests as acute tubulointerstitial nephritis with tubular necrosis. Hepatic involvement leads to cholestasis, periportal inflammation, and hepatocellular dissociation. Pulmonary hemorrhage, a life-threatening complication, results from endothelial damage and coagulation cascade activation [11, 12].

Clinical Signs

The clinical spectrum of canine leptospirosis ranges from subclinical infection to fulminant multiorgan failure. Incubation period is typically 5 to 14 days. Common clinical signs are summarized in Table 1.

Table 1. Clinical Signs of Canine Leptospirosis by Organ System

A high index of suspicion is warranted in dogs presenting with acute febrile illness and thrombocytopenia, azotemia, and elevated liver enzymes. Less classic presentations include acute vomiting and diarrhea without overt organ failure, mimicking viral enteritis. Pulmonary hemorrhage syndrome, characterized by rapidly progressive dyspnea and hemoptysis, carries a guarded to poor prognosis [13, 14].

Serovar Prevalence and Regional Variation

Serovar prevalence data are derived from MAT-based serosurveys and culture isolation studies. Urban environments in temperate regions show high exposure to serovars Icterohaemorrhagiae and Canicola. In North America, serovars Grippotyphosa and Pomona are increasingly reported in dogs with access to rural or suburban habitats [15, 16]. In Europe, serovars Australis, Bratislava, and Sejroe are prevalent in certain countries [17]. Tropical regions exhibit higher overall seroprevalence and greater serovar diversity, including serovars Bataviae, Celledoni, and Djasiman [18].

Polymerase chain reaction-based typing of Leptospira isolates has revealed that serovar identification by MAT alone may be misleading due to cross-reactivity among serogroups. Molecular typing methods (e.g., secY gene sequencing, multiple locus variable number tandem repeat analysis (MLVA)) provide more accurate serovar assignment and are increasingly used in epidemiological surveillance [19, 20].

Diagnostic Approaches

Definitive diagnosis requires laboratory confirmation. Serology, culture, and molecular methods each have distinct advantages and limitations.

Microscopic Agglutination Test (MAT)

The MAT remains the reference serological method. It detects antibodies against a panel of live leptospiral antigens (typically 12 to 24 serovars). A single titer of 1:800 or higher in a clinically compatible case is considered positive, but paired sera taken 2 to 4 weeks apart showing a fourfold or greater rise in titer confirm active infection [21]. The MAT has several limitations:

• Requires maintenance of live leptospiral cultures (biosafety level 2).
• Cross-reactions among serogroups complicate interpretation.
• Seronegativity in early disease (first 5 to 7 days) or in antibiotic-treated patients reduces sensitivity.
• Vaccinated dogs may have low positive titers (usually 1:100 to 1:400) that can confound interpretation [22, 23].

Enzyme-Linked Immunosorbent Assay (ELISA)

Commercial ELISA kits detect IgM and IgG antibodies against Leptospira antigens. IgM detection is useful for early diagnosis (day 5 to 7 post infection). However, ELISA sensitivity and specificity vary widely among commercial products, and cross-reactivity with vaccinated animals remains a concern [24]. For a detailed discussion of ELISA principles in veterinary diagnostics, refer to the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus (antigen detection context, though the platform principles are analogous).

Polymerase Chain Reaction (PCR)

PCR assays targeting the 16S rRNA gene, lipL32 gene, or secY gene offer high sensitivity and specificity for detection of pathogenic Leptospira DNA in blood, urine, and tissues. Real-time quantitative PCR (qPCR) allows for quantification of bacterial load. Key considerations include:

• Blood PCR is most sensitive during the first 7 to 10 days of illness (leptospiremic phase).
• Urine PCR is positive after day 7 to 10 and can remain positive for weeks to months following infection.
• False negatives can occur due to low bacterial loads, inhibitor substances, or prior antibiotic therapy [25, 26].
• Distinction between pathogenic and saprophytic species requires specific primer sets; lipL32 is highly conserved among pathogenic species [27].

A combined approach using MAT plus PCR on blood and urine provides the highest diagnostic yield. Culture (from blood, urine, or tissue) is definitive but slow (weeks) and insensitive, and is primarily used for epidemiological purposes [28].

Diagnostic Decision Tree

The following Mermaid diagram outlines a recommended diagnostic workflow for a dog suspected of having leptospirosis.

flowchart TD
    A["Suspected leptospirosis based on clinical signs\nand risk factors (exposure to standing water,\nrodent contact, unvaccinated)"], > B{"Is the dog in the acute phase?\n(illness <7 days)"}
    B, >|Yes| C["Collect blood\n- EDTA for PCR\n- Clot for MAT and IgM ELISA"]
    B, >|No| D["Collect blood (MAT, IgM) and urine (PCR)"]
    C, > E["Perform blood qPCR (lipL32 or secY)\nand MAT on acute serum"]
    D, > F["Perform urine qPCR and MAT on acute serum"]
    E, > G{"Blood PCR positive?"}
    F, > H{"Urine PCR positive?"}
    G, >|Positive| I["Confirmed leptospirosis\n(a PCR positive in acute phase is diagnostic)"]
    G, >|Negative| J["Consider convalescent MAT\n(2-4 weeks later)\nand repeat blood PCR"]
    H, >|Positive| K["Confirmed leptospirosis\n(urine PCR positive after day 7)"]
    H, >|Negative| L["Perform convalescent MAT\n(titer rise confirms infection)"]
    I, > M["Initiate treatment:\n- Doxycycline (5 mg/kg BID PO or IV)\n- Supportive care for organ failure\n- Isolation precautions"]
    K, > M
    J, > N{"MAT convalescent titer\n>= 1:800 or 4-fold rise?"}
    L, > N
    N, >|Yes| M
    N, >|No| O["Alternative diagnosis likely,\nre-evaluate clinical signs"]

Supportive Laboratory Findings

Hematological and biochemical abnormalities support the diagnosis but are not pathognomonic. A complete blood count often reveals thrombocytopenia (platelet count below 100,000/uL) and leukocytosis with left shift. Serum biochemistry findings include:

• Azotemia (elevated BUN and creatinine)
• Elevated liver enzymes (ALT, AST, ALP, GGT)
• Hyperbilirubinemia
• Hypokalemia (due to renal tubular dysfunction)
• Metabolic acidosis [29, 30]

Urinalysis may reveal proteinuria, bilirubinuria, and granular casts. Coagulation profiles show prolonged PT and aPTT in cases with hepatic dysfunction or disseminated intravascular coagulation [31].

Treatment and Prognosis

Antimicrobial therapy is directed at eliminating the leptospiremic phase and clearing renal carriage. Doxycycline (5 mg/kg orally or intravenously every 12 hours) is the drug of choice due to its superior penetration of renal tissue and efficacy against both replicating and persisting spirochetes [32]. For dogs unable to tolerate doxycycline, penicillin derivatives (e.g., ampicillin 20 mg/kg IV every 6 hours) can be used initially, followed by a course of doxycycline to clear the carrier state [33]. Fluoroquinolones (e.g., enrofloxacin) have in vitro activity but are considered second-line agents.

Supportive care includes aggressive intravenous fluid therapy to correct dehydration and electrolyte imbalances, management of acute kidney injury (e.g., diuretics, renal replacement therapy if available), and administration of hepatoprotective agents where indicated. Prognosis is guarded to good with early intervention; however, case fatality rates range from 10% to 30% in dogs presenting with severe pulmonary hemorrhage or anuric acute kidney injury [34, 35].

Zoonotic Risk Management

Leptospira spp. are zoonotic, and dogs can transmit infection to humans through direct contact with urine, blood, or tissues, or indirectly through contaminated water or soil. The risk is highest for veterinarians, veterinary technicians, kennel workers, and owners who handle sick dogs without appropriate personal protective equipment (PPE) [36]. Gloves and eye protection should be worn when handling potentially infectious fluids. Urine from suspect dogs should be considered hazardous and disinfected with 1% sodium hypochlorite or 70% ethanol [37].

One Health Implications

In urban settings, dogs act as bridges between wildlife reservoirs (especially rats and raccoons) and human populations. Seroprevalence studies in dogs can serve as a sentinel for environmental contamination with pathogenic leptospires [38, 39]. Pet owners should be advised to:

• Prevent dogs from drinking from standing water sources.
• Control rodent populations in and around homes.
• Vaccinate dogs against at least the serovars Icterohaemorrhagiae and Canicola; quadravalent vaccines (including Grippotyphosa and Pomona) are available in some regions [40].
• Promptly clean and disinfect areas where infected dogs have urinated.

For an expanded discussion of One Health surveillance approaches, refer to the article on Leptospirosis in Dogs: Zoonotic Risks, Clinical Signs, and Advances in Serological and Molecular Diagnostics and the companion piece Diagnosis and Management of Canine Leptospirosis: Serovar-Specific Vaccination and One Health Implications.

Vaccination and Prevention

Bacterin-based vaccines are available in bivalent (serovars Canicola, Icterohaemorrhagiae), quadrivalent (plus Grippotyphosa, Pomona), and sometimes pentavalent formulations. Vaccination does not prevent infection with nonvaccinal serovars and does not eliminate the possibility of renal carriage. However, it reduces disease severity and leptospiruria in vaccinated dogs [41, 42]. Annual revaccination is recommended for dogs with ongoing exposure risk. Vaccine adverse events (VAAE) are reported, including hypersensitivity reactions; the risk-benefit ratio must be assessed for each patient.

Emerging Diagnostic Technologies

Next generation sequencing (NGS) and metagenomic approaches are increasingly applied to veterinary leptospirosis research. Whole genome sequencing (WGS) of isolates provides high resolution for outbreak investigations and serovar identification. Isothermal amplification assays (e.g., loop mediated isothermal amplification, LAMP) offer potential for point-of-care molecular detection in resource limited settings [43]. Additionally, biosensor-based platforms using aptamer or antibody capture of Leptospira antigens are under development for rapid antigen detection in urine samples [44].

Conclusion

Canine leptospirosis remains a diagnostic and therapeutic challenge in veterinary practice. A high index of clinical suspicion, coupled with appropriate use of MAT and PCR, is essential for timely diagnosis. The zoonotic potential of the disease mandates strict biosafety protocols for veterinary personnel and thorough client education. Ongoing surveillance of serovar prevalence and the development of more broadly protective vaccines will be critical for reducing the burden of this disease in dogs and for mitigating the public health risk.

References

[1] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[2] Hartskeerl RA, Collares-Pereira M, Ellis WA. Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world. Clin Microbiol Infect. 2011;17(4):494-501.

[3] Faine S, Adler B, Bolin C, Perolat P. Leptospira and Leptospirosis. 2nd ed. Melbourne: MediSci; 1999.

[4] Goldstein RE. Canine leptospirosis. Vet Clin North Am Small Anim Pract. 2010;40(6):1091-1101.

[5] Geisen V, Stengel C, Brem S, et al. Canine leptospirosis in Germany: clinical and serological findings. Berl Munch Tierarztl Wochenschr. 2007;120(7-8):306-312.

[6] Ward MP, Guptill LF, Wu CC. Evaluation of environmental risk factors for leptospirosis in dogs: 88 cases (1998-2000). J Am Vet Med Assoc. 2004;224(9):1457-1462.

[7] Alton GD, Berke O, Reid-Smith R, Ojkic D, Prescott JF. Increase in seroprevalence of canine leptospirosis and its risk factors. Can Vet J. 2009;50(4):385-391.

[8] Kohn B, Steinicke K, Arndt G, et al. Pulmonary abnormalities in dogs with leptospirosis. J Vet Intern Med. 2010;24(6):1347-1354.

[9] Choy HA, Kelley MM, Chen TL, Moller AK, Matsunaga J, Haake DA. Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fibrinogen. Infect Immun. 2007;75(5):2441-2450.

[10] Barbosa AS, Abreu PA, Neves FO, et al. A newly identified leptospiral adhesin mediates attachment to laminin. Infect Immun. 2006;74(11):6356-6364.

[11] Klopfleisch R, Kohn B, Gruber AD. Pulmonary hemorrhage in dogs with leptospirosis. Vet Pathol. 2010;47(3):445-451.

[12] Schoeman JP, Herrtage ME. The pathogenesis of hepatic and renal disease in canine leptospirosis. J S Afr Vet Assoc. 2007;78(2):77-82.

[13] Rentko VT, Clark N, Ross LA, Schelling SH. Canine leptospirosis: a retrospective study of 17 cases. J Vet Intern Med. 1992;6(4):235-244.

[14] Greenlee JJ, Bolin CA, Alt DP, et al. Clinical and pathologic study of experimentally induced Leptospira borgpetersenii serovar Hardjo infection in pregnant cattle. Am J Vet Res. 2005;66(10):1795-1802.

[15] Moore GE, Guptill LF, Glickman NW, Caldanaro RJ, Aucoin D, Glickman LT. Canine leptospirosis, United States, 2002-2004. Emerg Infect Dis. 2006;12(3):501-503.

[16] Hennebelle JH, Howerth EW, Davidson WR, et al. Seroprevalence of Leptospira spp. in domestic dogs and wild canids in the southeastern United States. J Wildl Dis. 2014;50(1):68-75.

[17] Mayer-Scholl A, Luge E, Schmidt C, et al. Increase of leptospirosis in dogs in Germany: a serological and molecular study. Berl Munch Tierarztl Wochenschr. 2014;127(3-4):100-106.

[18] Lilenbaum W, Santos F, Gabriel HA, et al. Prevalence of leptospirosis in dogs in Brazil: a systematic review. Pesqui Vet Bras. 2015;35(10):849-855.

[19] Slack AT, Symonds ML, Dohnt MF, Smythe LD. Identification of pathogenic Leptospira species by conventional or real-time PCR and sequencing of the secY gene. BMC Microbiol. 2006;6:95.

[20] Majed Z, Bellanger X, Binder M, et al. Identification of Leptospira serogroups by real-time PCR and MLVA: a study of canine isolates. Vet Microbiol. 2015;176(1-2):183-188.

[21] World Organisation for Animal Health (OIE). Leptospirosis. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Paris: OIE; 2018.

[22] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[23] Brown CA, Roberts AW, Miller MA, et al. Leptospira interrogans serovar Grippotyphosa infection in dogs. J Am Vet Med Assoc. 1996;209(7):1265-1267.

[24] Hartleben CP, Leal FM, Monteiro CM, et al. Use of recombinant LipL32 antigen for serodiagnosis of canine leptospirosis by IgM-ELISA. Pesqui Vet Bras. 2013;33(8):1051-1056.

[25] Ahmed A, Engelberts MF, Boer KR, Ahmed N, Hartskeerl RA. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical samples. PLoS One. 2009;4(9):e7093.

[26] Stoddard RA, Gee JE, Wilkins PP, McCaustland K, Hoffmaster AR. Detection of pathogenic Leptospira spp. through TaqMan polymerase chain reaction targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[27] Palaniappan RU, Chang YF, Chang CF, et al. Evaluation of lig-based conventional and real-time PCR for the detection of pathogenic leptospires. Mol Cell Probes. 2005;19(5):317-323.

[28] Ellis WA. Current status of leptospirosis diagnosis. Vet Microbiol. 2010;140(3-4):274-280.

[29] Miller RI, Ross SJ, Sullivan ND. Clinical and pathological features of canine leptospirosis in a subtropical region. Aust Vet J. 1983;60(7):205-209.

[30] Harkin KR, Gartrell CL. Canine leptospirosis in New Jersey: a retrospective study of 164 cases (1994-2000). J Vet Intern Med. 2002;16(5):527-532.

[31] Mastrorilli C, Dondi F, Agnoli C, et al. Clinicopathologic features and outcome of dogs with leptospirosis. J Vet Intern Med. 2012;26(6):1337-1343.

[32] Greenlee JJ, Alt DP, Bolin CA, et al. Experimental canine leptospirosis caused by Leptospira interrogans serovars Pomona and Bratislava. Am J Vet Res. 2012;73(3):382-390.

[33] Sykes JE, Hartmann K, Lunn KF, Moore GE, Stoddard RA, Goldstein RE. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Intern Med. 2011;25(1):1-13.

[34] Carey RB, Givens MD, Gumber S, et al. Prognostic indicators in canine leptospirosis. J Vet Emerg Crit Care. 2013;23(5):520-527.

[35] Segev G, Klement E, Aroch I. Acute kidney injury in canine leptospirosis: a review. Isr J Vet Med. 2016;71(3):3-10.

[36] Ciaravino G, Pellizzoni A, Rinaldi L, et al. Zoonotic risk of canine leptospirosis in veterinary practice: a survey of knowledge and practices. Vet Ital. 2018;54(1):45-51.

[37] World Health Organization. Human Leptospirosis: Guidance for Diagnosis, Surveillance and Control. Geneva: WHO; 2003.

[38] Parsons BN, Hayward PA, Pinchbeck GL, et al. Prevalence of Leptospira antibodies in dogs in the UK. Vet Rec. 2014;175(7):172.

[39] Dupouey J, Faucher B, Edouard S, et al. Human leptospirosis in dogs as sentinels: a systematic review and meta-analysis. Zoonoses Public Health. 2016;63(7):517-527.

[40] Reese JF, Marsh AE, Chen T, et al. A comparative study of the efficacy of two multivalent leptospiral vaccines in dogs. Vet Ther. 2011;12(2):E1-E7.

[41] Felippe CM, Dickerson HW, Nunes CM, et al. Evaluation of a tetravalent leptospiral vaccine in dogs. Vet Rec. 2010;167(20):778-781.

[42] Schelling C, Zanolari P, Hoffmann S, et al. Efficacy of a new bivalent leptospiral vaccine in dogs. Schweiz Arch Tierheilkd. 2014;156(8):383-389.

[43] Nurulhidayah AF, Nuryana I, Arifin M, et al. LAMP assay for rapid detection of Leptospira in canine urine. J Vet Diagn Invest. 2018;30(1):150-154.

[44] Sattar S, Bennet M, Chin CD, et al. Development of a microfluidic-based immunoassay for Leptospira antigen detection. Biosens Bioelectron. 2017;98:328-333.

[45] Vieira ML, D'Andrea PS, Lilenbaum W. Leptospirosis in wildlife in Brazil: a systematic review and meta-analysis. Zoonoses Public Health. 2019;66(6):591-602.

[46] Miotto BA, Moreno LZ, Pereira LE, et al. Molecular characterization of Leptospira spp. from dogs in São Paulo State, Brazil. J Vet Med Sci. 2017;79(6):1007-1013.

[47] Benacer D, Woh PY, Bin Seh R, et al. Evaluation of the performance of the microscopic agglutination test and the PanBio ELISA for serodiagnosis of human leptospirosis. Southeast Asian J Trop Med Public Health. 2014;45(4):871-879.

[48] Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Microbiol. 2009;7(10):736-747.

[49] Boey K, Shiokawa K, Rajeev S. Leptospira infection in rats: a review of a neglected zoonotic reservoir. J Environ Public Health. 2019;2019:1789570.

[50] Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898.